Clinical trial
A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
NCT00294762 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers
- Lead sponsor
- OSI Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2006
- Completion date
- March 31, 2009
- Enrollment
- 143 (actual)
- Sites
- 43
Conditions
As the registry lists them; a condition with its own page is linked.